Moxifloxacin for tuberculosis

The Lancet Infectious Diseases

Volumn 12, Issue 3, 2012, Pages 176-

  Singh, Kasha Priya ^a   Brown, Michael ^b   Murphy, Michael E ^a   Gillespie, Stephen H ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; TUBERCULOSTATIC AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; NEW DRUG; OFLOXACIN;

BACTERIAL TRANSMISSION; BACTERIUM MUTANT; CROSS RESISTANCE; DRUG COST; HEALTH PROGRAM; HUMAN; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RISK REDUCTION; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; DRUG EFFECT; MYCOBACTERIUM TUBERCULOSIS; NOTE; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; DRUG EFFICACY; PATIENT SELECTION; PRESCRIPTION; TREATMENT RESPONSE; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS;

EID: 84857162957     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70350-4     Document Type: Letter

References (6)

1. Cox H, Ford N, Keshavjee S, et al. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis 2011, 11:259-260.
2. Nunn AJ, Phillips PP, Gillespie SH Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis 2008, 88(suppl 1):S85-S92.
3. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
4. Salomon JA, Lloyd-Smith JO, Getz WM, et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 2006, 3:e273.
5. Gillespie SH, Basu S, Dickens AL, O'Sullivan DM, McHugh TD Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 2005, 56:344-348.
6. Von Groll A, Martin A, Jureen P, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009, 53:4498-4500.